EXOZYMES INC.

Listed Company

EXOZCIK 0002010788NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthBiological Products, (No Diagnostic Substances)NevadaFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-9.16M

Total Assets

$5.97M

Equity

$3.40M

Shares Out

8.48M

Op. Cash Flow

$-6.50M

Business

eXoZymes Inc. develops and commercial cell-free biomanufacturing technology based on AI-designed, engineered enzymes called exozymes. It offers exozyme biosolutions and related services to convert affordable feedstocks into valuable chemicals, including small-molecule active pharmaceutical ingredients (APIs), nutraceuticals, specialty natural products and biofuels such as isobutanol. Its activities encompass a technology and R&D platform, enzyme/exozyme production, pilot-scale manufacturing, IP development, and commercialization via spin-outs, joint ventures and licensing. The company distributes its solutions through partnerships, grants, collaborations and licensing arrangements in U.S. and international markets.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Total operating income	—	—	70,069
Compensation	4	3	596,174
Professional fees	1	1	436,338
Information technology	95,989	38,658	21,803
General and administrative-other	836,076	329,660	284,496
Total general and administrative costs	6	4	1
Research and development costs	4	2	527,480
Total operating costs	10	6	2
Net operating loss	−10	−6	−2
Interest income, net	363,786	77,612	100
Other income/(expense)	88,746	−6,834	—
Change in fair value of SAFE	—	−8	−200,000
Loss before income taxes	−9	−6	−2
Income tax benefit	105,205	—	−42,267
Net loss	−9	−6	−2
Net loss per common share - basic	−1.09	−0.89	−0.33
Net loss per common share - diluted	−1.09	−0.89	−0.33
Weighted average of common shares outstanding - basic	8	7	6
Weighted average of common shares outstanding - diluted	8	7	6

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	3	10	66,533	—
Grants receivable	517,359	737,282	882,319	809,532
Prepaid expenses and other current assets	382,886	363,790	264,762	—
Total current assets	4	11	1	—
Property and equipment, net	764,401	882,445	753,376	—
Operating lease right-of-use asset, net	1	1	2	—
Finance lease right-of-use asset, net	108,682	—	—	—
Tax receivable	105,205	—	—	—
Total assets	6	13	4	—
Accounts payable	1	924,252	702,911	—
Due to affiliates	5,330	178,966	445,128	—
Operating lease liabilities Current	281,979	230,027	224,988	—
Finance lease liabilities Current	44,255	—	—	—
Total current Liabilities	2	1	2	—
Deferred grant reimbursement	90,365	123,579	140,703	—
Operating lease liabilities - Long term	852,575	1	1	—
Finance lease liabilities - Long term	64,427	—	—	—
Total liabilities	3	3	4	—
Preferred stock, $0.000001 par value, 5,000,000 shares authorized; no shares issued and outstanding on December 31, 2025, and December 31, 2024, respectively.	—	—	—	—
Common shares, 100,000,000 authorized shares at $0.000001; 8,406,681 and 8,367,810 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively	8	8	6	—
Additional Paid-in-capital	25	22	6	—
Accumulated (deficit)	−21	−12	−6	—
Total stockholders equity	3	10	−384,319	1
Total liabilities and stockholders equity (deficit)	6	13	4	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Amortization of Deferred Grant Reimbursement	−52,913	−54,359	−51,840
Depreciation of property and equipment	287,961	267,382	196,937
Non-cash lease expense	53,367	34,955	10,570
Stock-based compensation	2	1	281,538
Change in fair value of SAFE	—	8	200,000
Grants receivable	219,923	145,037	−72,787
Prepaid expenses and other current assets	−19,096	−99,028	−163,625
Tax receivable	−105,205	—	—
Accounts payable and accrued expenses	311,085	221,340	272,890
Due to related party	−26,533	−4	205,128
Tax payable	—	−42,267	−21,292
Net cash (used in) operating activities	−7	−9	−1
Deferred grant reimbursement	19,699	37,235	−22,455
Purchases of property and equipment	−169,917	−396,451	−288,712
Net cash (used in) investing activities	−150,218	−359,216	−311,167
Issuance of common shares	—	15	—
Related Party Note	—	4	—
Issuance of Warrants for Private placement	—	11,819	—
Payments on finance lease obligations	−27,709	—	—
Net cash provided by (used in) financing activities	−27,709	19	1
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS	−7	10	−492,037
Interest Expense	6,252	—	—
Income Taxes	—	—	63,559
Conversion of SAFE Note to common shares	—	1	—
Related party debt forgiveness	147,103	—	—
Right-of-use assets obtained in exchange for new lease liabilities	136,391	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro